Umeclidinium bromide/vilanterol
Combination of | |
---|---|
Umeclidinium bromide | Muscarinic antagonist |
Vilanterol | Ultra-long-acting β2 agonist |
Names | |
Trade names | Anoro Ellipta, Laventair Ellipta |
Clinical data | |
Pregnancy category |
|
Routes of use | Inhalation (DPI) |
External links | |
AHFS/Drugs.com | Professional Drug Facts |
Legal | |
License data | |
Legal status |
Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease (COPD).[3][4] It is applied as an inhalation.
The most common side effects include upper respiratory tract infections (nose and throat infection), urinary tract infections (infection of the structures that carry urine), pharyngitis (inflammation of the throat), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache, cough, oropharyngeal pain (pain in the mouth and throat), constipation and dry mouth.[1]
Society and culture
Cost
The cost of 60 blisters of 62.5 mg umeclidinium/25 mcg vilanterol in this medication is $425 to $500 (USD) for one inhaler [5]
-
Umeclidinium bromide/vilanterol costs (US)
-
Umeclidinium bromide/vilanterol prescriptions (US)
References
- ↑ 1.0 1.1 "Anoro Ellipta EPAR". European Medicines Agency (EMA). Archived from the original on 11 November 2020. Retrieved 28 October 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Anoro Ellipta 55 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 7 October 2019. Archived from the original on 29 August 2021. Retrieved 29 October 2020.
- ↑ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282. Archived from the original on 2021-08-29. Retrieved 2020-02-02.
- ↑ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013. Archived from the original on September 24, 2017. Retrieved January 13, 2014.
- ↑ "How much does Anoro Ellipta cost without insurance?". Drugs.com. Archived from the original on 29 August 2021. Retrieved 9 April 2021.
External links
Identifiers: |
---|
- "Umeclidinium bromide mixture with vilanterol". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2021-08-29. Retrieved 2020-10-29.
- Pages using duplicate arguments in template calls
- Drugs with non-standard legal status
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Beta-adrenergic agonists
- Combination drugs
- Drugs acting on the respiratory system
- Long-acting beta2-adrenergic agonists
- Muscarinic antagonists
- GlaxoSmithKline brands
- All stub articles
- Respiratory system drug stubs